| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
CVS HEALTH CORPORATION$100.3
-1.13 (-1.11%)
0Pipeline Score NOT_PHARMA
Market Cap
100.92 B
EPS
1.40
P/E Ratio
57.34 $
Value Trade
694.17 M
SEC Financials
Q1 2026Dilution Risk
Revenue
100.43 B
Operating CF
4.25 B
Total Assets
252.97 B
Total Liabilities
175.34 B
Equity
77.46 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
11.80 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
530.31 K
52 Week Range
58.35 - 85.15
% held by Insiders
0.2 %
% held by Institutions
90.37 %
Enterprise Value
170.39 B
Total Shares
1.28 B
Short %
1.41 %
Float Shares
1.26 B
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
0
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 3%
Micro Cap (rank 879 of 905)
Percentile RankClinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CVS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CVS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CVS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-CVS
Jun 5, 2026AM Best Affirms Credit Ratings of CVS Health Corporation’s Aetna Inc. Subsidiaries
AM Best has affirmed the credit ratings of CVS Health Corporation's Aetna Inc. subsidiaries. This affirmation indicates stability in the financial standing of these subsidiaries. No specific details about the ratings or the implications were provided in the article.
Read more →-CVS
May 29, 2026CVS Health recognized for technology that improves medication safety and patient care
CVS Health has been awarded the 2026 Newsweek AI Impact Award for its AI-Driven Prescription Interpretation technology, which enhances medication safety and patient care. This innovation automates complex prescription processing, allowing pharmacists to dedicate more time to patient support. The technology has shown measurable improvements in both retail and specialty pharmacy settings.
Read more →-CVS
May 28, 2026CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options
CVS Health announced expanded coverage options for GLP-1 weight management medications, including the reintroduction of Zepbound. Effective October 1, 2026, this move aims to enhance affordability and access for plan sponsors and their members. CVS Caremark's initiatives have historically led to significant savings, while ongoing negotiations with manufacturers seek to further reduce costs. However, high prices continue to pose challenges for some customers.
Read more →-CVS
May 28, 2026Aetna launches Aetna Mental Health On Demand to provide real time access to care and ongoing support
Aetna has launched Aetna Mental Health On Demand, providing real-time access to mental health care for members aged 13 and older. The service allows members to connect with licensed clinicians through chat, phone, or video, ensuring immediate support and personalized care plans. This initiative aims to address the unmet mental health needs reported by many adults and is set to launch in January 2027.
Read more →-CVS
May 26, 2026Aetna reduces claims processing time by more than 20% with AI to improve care experience
Aetna has launched the second generation of its Claims Assist Manager (CAM), an AI-driven platform that streamlines claims processing and enhances payment accuracy. This innovation reduces processing time by over 20% for complex claims, addressing provider feedback on administrative burdens. CAM is part of CVS Health's broader $20 billion investment in digital healthcare solutions.
Read more →-CVS
May 21, 2026CVS Health, Diocese of Camden, and The Walters Group Unite to Bring Senior Affordable Housing to Williamstown, New Jersey
CVS Health has partnered with the Diocese of Camden and The Walters Group to open Mews at St. Mary, a new 75-unit affordable housing facility for seniors in Williamstown, New Jersey. This initiative, supported by a $9 million investment from CVS Health, aims to provide stable housing and essential health services to older adults. The project reflects CVS Health's ongoing commitment to improving community health and addressing housing insecurity in the state.
Read more →-CVS
May 20, 2026CVS Health Reinforces Longstanding Support for the Military Community
CVS Health is reinforcing its commitment to the military community by providing comprehensive support to service members, veterans, and their families. The company focuses on health care access, community solutions, and economic opportunities tailored to the unique challenges faced by military-connected individuals. Through partnerships with various organizations, CVS Health aims to enhance the well-being and stability of military families across the nation.
Read more →-CVS
May 14, 2026CVS Health® and WGU launch online pre-pharmacy degree program for future pharmacists nationwide
CVS Health and WGU have launched an online pre-pharmacy degree program aimed at reducing financial barriers for aspiring pharmacists. This program allows CVS colleagues to complete foundational courses at a lower cost while maintaining their jobs. The initiative is part of CVS's broader strategy to enhance the pharmacy workforce and support career advancement.
Read more →-CVS
May 13, 2026Omnicare Receives Court Approval for Sale of Business to GenieRx
Omnicare, a subsidiary of CVS Health, has received court approval for its sale to GenieRx Holdings LLC. This transaction is expected to enhance Omnicare's pharmacy services and operational practices. The sale reflects confidence in Omnicare's longstanding customer relationships and commitment to care. The deal is set to close later this year, pending regulatory approval.
Read more →-CVS
May 6, 2026CVS HEALTH CORPORATION REPORTS STRONG FIRST QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE
CVS Health Corporation reported strong first quarter results for 2026, with total revenues reaching $100.4 billion, a 6.2% increase from the previous year. The company also raised its full-year guidance for both GAAP and adjusted EPS, reflecting confidence in its operational performance. However, CVS remains cautious about potential macroeconomic challenges that could affect its outlook.
Read more →-CVS
May 5, 2026CVS Caremark Expands Biosimilar Adoption Through Formulary Updates to Improve Affordability and Access
CVS Health announced updates to its commercial formularies to enhance the adoption of lower-cost biosimilars, effective July 1, 2026. The changes will prefer interchangeable biosimilars over select reference brands, aiming to reduce drug costs while maintaining clinical quality. This initiative is part of CVS's broader strategy to improve affordability and access to medications for its members.
Read more →-CVS
Apr 27, 2026CVS Health Wins Gold in Enterprise AI, and Silver in Customer Experience AI at 2026 Stevie® (American Business Awards®) for Enterprise Scale AI Innovation
CVS Health has been awarded Gold in Enterprise AI and Silver in Customer Experience AI at the 2026 Stevie Awards. The recognition underscores CVS's commitment to deploying responsible AI that enhances healthcare operations and customer experiences. Judges commended CVS for its innovative AI systems that improve efficiency and patient care.
Read more →-CVS
Apr 24, 2026Aetna Announces Progress on Industry Leading Efforts to Simplify Prior Authorization
Aetna, a CVS Health company, has made significant strides in simplifying prior authorization processes, achieving an 88% standardization of its volume. The company boasts a high approval rate of over 95% for eligible requests within 24 hours and has automated many processes to enhance efficiency. Aetna is also pioneering integrated reviews for medical and pharmacy decisions, improving the overall experience for patients and providers.
Read more →-CVS
Feb 10, 2026CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS Fourth Quarter Highlights Total revenues increased to $105.7 billion, up 8.2% compared to prior year GAAP diluted EPS of $2.30 and Adjusted EPS of
CVS Health Corporation reported robust financial results for the fourth quarter and full-year 2025, with total revenues increasing to $105.7 billion in Q4 and a record high of $402.1 billion for the year. The company posted a GAAP diluted EPS of $2.30 for Q4 and an adjusted EPS of $6.75 for the full year, although the adjusted EPS saw a slight decline compared to the previous year. Despite strong revenue growth, CVS faced challenges, including a significant drop in operating income primarily due to impaired assets and litigation costs. The company reaffirmed its guidance for 2026, positioning itself strongly within the health care sector.
Read more →-CVS
Dec 9, 2025CVS Health Updates Financial Guidance, Highlights Strength of Businesses, and Announces Strategy to Uniquely Reimagine Health Care at Investor Day Event Outlines strategy to deliver best-in-class execution, transform con
CVS Health recently held its 2025 Investor Day, where it updated its financial guidance and outlined its strategy to enhance health care delivery. The company forecasts a mid-teens compound annual growth rate for Adjusted EPS by 2028, driven by strong performance across its diverse business segments. CVS also announced plans to launch an open consumer engagement platform aimed at improving access to health care services and consumer experiences. The company emphasized its commitment to being a trusted health care partner moving forward.
Read more →-CVS
Nov 20, 2025WOONSOCKET, RI (
CVS Health has appointed David Joyner as Chair of the Board, effective January 1, 2026. Joyner, who became President and CEO in October 2024, has made notable operational and cultural advancements within the company. The Board believes that having one leader in both roles will facilitate the execution of its long-term strategy. CVS Health aims to provide a simplified and connected health care experience for its customers.
Read more →-CVS
Oct 29, 2025CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE Financial Highlights Third quarter total revenues increased to a record high $102.9 billion, up 7.8% compared to prior year Th
CVS Health Corporation has reported its third-quarter results for 2025, with revenues increasing to a record high of $102.9 billion, up 7.8% from the previous year. Despite this revenue growth, the company faced a significant GAAP diluted loss per share of $3.13 due to a $5.7 billion goodwill impairment charge. The updated full-year guidance reflects mixed performance across segments, with improvements in Health Care Benefits but challenges in Health Services. CEO David Joyner emphasized CVS's commitment to enhancing customer experience and operational stability.
Read more →-CVS
Sep 22, 2025Omnicare Initiates Voluntary Chapter 11 Process Company Intends to Use Process to Implement a Standalone Restructuring or Sale Strategy Remains Focused on Delivering Safe and Reliable Pharmacy Servi
Omnicare, a subsidiary of CVS Health, has initiated a voluntary Chapter 11 process to address litigation issues and financial challenges in the long-term care pharmacy industry. The company aims to use this process to explore restructuring options, while continuing to provide pharmacy services without disruption. Omnicare secured $110 million in debtor-in-possession financing to support ongoing operations during this court-supervised process, maintaining its commitment to customer care and support for stakeholders.
Read more →-CVS
Jul 31, 2025CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE Financial Highlights Second quarter total revenues increased to $98.9 billion, up 8.4% compared to prior year Second quarter
CVS Health Corporation reported its Q2 2025 financial results, showing total revenues of $98.9 billion, an 8.4% increase year-over-year. Despite a drop in GAAP diluted EPS to $0.80 due to litigation charges, the company raised its Adjusted EPS guidance. Significant operational highlights include CVS Pharmacy's planned acquisition of Rite Aid stores and a $20 billion commitment to improving U.S. healthcare systems over the next decade. The company faces challenges with decreasing operating income and medical membership, which could impact future performance.
Read more →-CVS
May 1, 2025CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE First Quarter Financial Highlights Total revenues increased to $94.6 billion, up 7.0% compared to prior year GAAP diluted EPS
CVS Health Corporation reported a 7.0% increase in total revenues for Q1 2025, reaching $94.6 billion, driven by strong performance across its business segments. Adjusted earnings per share (EPS) were raised, reflecting improvements particularly in the Health Care Benefits sector. However, the company announced plans to exit the individual exchange business and noted substantial litigation charges that could affect its financial outlook. Overall, while CVS Health shows positive growth, it faces significant operational challenges ahead.
Read more →-CVS
Apr 8, 2025CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer WOONSOCKET, RI (DATE) CVS Health (NYSE: CVS) today announced two leadership updates. Brian O. Newman has been nam
CVS Health has announced key leadership changes, appointing Brian O. Newman as the Chief Financial Officer and Dr. Amy Compton-Phillips as the Chief Medical Officer. Newman brings extensive experience from UPS and PepsiCo, while Compton-Phillips has a strong background in healthcare management. These appointments are aimed at strengthening the company's strategy and enhancing healthcare delivery to its millions of patients. CVS Health aims to leverage these leaders' expertise to improve patient outcomes and operational efficiency.
Read more →-CVS
Feb 12, 2025CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2024 RESULTS Fourth Quarter Highlights Total revenues increased to $97.7 billion, up 4.2% compared to prior year GAAP diluted EPS of $1.30 and Adjusted EPS of $
CVS Health Corporation reported its fourth quarter and full-year 2024 results, revealing a total revenue increase of 4.2% compared to the previous year, reaching $97.7 billion for the quarter and $372.8 billion for the full year. Despite the revenue growth, the company saw a decline in diluted earnings per share and adjusted operating income, largely due to pressures in the Health Care Benefits segment and unfavorable Medicare Advantage ratings. CEO David Joyner highlighted the company's integrated model and expressed confidence in future performance, despite current challenges.
Read more →-CVS
Dec 16, 2024Investor Larry McGrath Media Ethan Slavin Contact: Executive Vice President Contact: 860-273-6095 Chief Strategy Officer & Chief Strategic Advisor to the CEO investorinfo@cvshealth.com Ethan.Slavin@CVSHealth.com FOR IMME
CVS Health Corporation announced the early results of its Maximum Tender Offer, outlined in a press release dated December 16, 2024. The company intends to purchase a maximum of $1.77 billion in various series of senior notes, with the early settlement date set for December 18, 2024. Notably, valid tenders have been submitted in significant amounts, indicating strong participation. Accrued interest will also be paid on accepted notes, showing the company’s commitment to manage its financial obligations effectively.
Read more →-CVS
Dec 9, 2024Investor Larry McGrath Media Ethan Slavin Contact: Executive Vice President Chief Strategy Officer & Chief Strategic Advisor to the CEO investorinfo@cvshealth.com Contact: 860-273-6095 Ethan.Slavin@CVSHealth.com FOR IMME
CVS Health Corporation announced the results of its cash tender offer for its 4.100% Senior Notes due 2025, set to expire on December 6, 2024. As part of the offer, the company expects to accept all notes validly tendered, with a settlement date anticipated on December 11, 2024. CVS will fund this purchase utilizing proceeds from its upcoming series of junior subordinated notes. This tender offer reflects CVS Health's ongoing efforts to manage its capital structure effectively.
Read more →-CVS
Dec 6, 2024Investor Larry McGrath Media Ethan Slavin Contact: Executive Vice President Contact: 860-273-6095 Chief Strategy Officer & Ethan.Slavin@CVSHealth.com Chief Strategic Advisor to the CEO investorinfo@cvshealth.com FOR IMME
CVS Health Corporation has announced a cash tender offer for its 4.100% Senior Notes due 2025. The offer includes a total consideration based on a fixed spread over the yield of U.S. Treasury securities. All registered holders of these notes are eligible to participate in this offer, which is set to expire on December 6, 2024. CVS has outlined the terms of the offer in its Offer to Purchase document and reserved the right to amend or terminate the offer at any time prior to its expiration date.
Read more →-CVS
Nov 18, 2024CVS Health Announces Board Appointments CVS Health Board of Directors appoints four new members: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman Appointments follow productive engagement with G
CVS Health has appointed four new members to its Board of Directors, including Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman. This decision follows productive discussions with Glenview Capital Management, signifying a commitment to enhancing shareholder value and operational performance. The new board members bring extensive industry experience and are expected to focus on driving innovation, improving customer experience, and maintaining high standards in compliance and risk management. With these additions, the board now consists of 16 members, further reinforcing CVS Health's leadership structure.
Read more →-CVS
Nov 6, 2024CVS Health Announces Leadership Appointments Prem Shah named Group President, CVS Health; Steve Nelson named President, Aetna WOONSOCKET, RI (
CVS Health has announced key leadership appointments, with Prem Shah taking on the role of Group President and Steve Nelson designated as President of Aetna. Shah, who has been with CVS since 2013, will oversee integrated operations across the company’s Caremark, Pharmacy, and Health Care Delivery sectors. Nelson, a former CEO of ChenMed and UnitedHealthcare, brings significant experience in managed care and is expected to enhance Aetna's growth and profitability. Both appointments are effective immediately and are expected to support CVS Health's integrated business strategy.
Read more →-CVS
Nov 6, 2024CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2024 RESULTS Financial Highlights Third quarter total revenues increased to $95.4 billion, up 6.3% compared to the prior year Third quarter GAAP diluted EPS of $0.07 and Adjus
CVS Health Corporation reported third quarter 2024 results, showing total revenues of $95.4 billion, up 6.3% year-over-year. However, the company experienced a significant decline in GAAP diluted earnings per share, dropping to $0.07 from $1.75 in the prior year. The decrease was largely attributed to restructuring charges and premium deficiency reserves related to anticipated losses in the Health Care Benefits segment. Despite these challenges, the company's operations in Health Services and the Pharmacy Consumer Wellness segments performed well.
Read more →-CVS
Oct 18, 2024CVS Health Appoints David Joyner President and Chief Executive Officer Roger Farah Named Executive Chairman of the Board Company provides preliminary guidance for third quarter 2024 GAAP diluted Earnings pe
CVS Health has appointed David Joyner as President and CEO, effective October 17, 2024, succeeding Karen Lynch. Joyner, who previously held key executive roles at CVS Health and has significant healthcare experience, aims to leverage his knowledge to address industry challenges. The company also provided preliminary guidance for Q3 2024, projecting GAAP diluted EPS in the range of $0.03 to $0.08, amid pressures from elevated medical costs and restructuring charges. These changes come as CVS Health continues its mission to improve healthcare access for millions of Americans.
Read more →-CVS
Aug 7, 2024CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE Financial Highlights Second quarter total revenues increased to $91.2 billion, up 2.6% compared to the prior year Second quar
CVS Health Corporation reported its second quarter results for 2024, showing a revenue increase of 2.6% to $91.2 billion. However, both diluted and adjusted earnings per share decreased, prompting the company to revise its full-year 2024 guidance downwards for GAAP and adjusted EPS. The decline was primarily attributed to challenges in the Health Care Benefits segment, while strong performance was noted in Health Services and Pharmacy Consumer Wellness. Leadership changes have been announced as part of efforts to address ongoing operational pressures.
Read more →-CVS
May 1, 2024CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE First Quarter Highlights Total revenues increased to $88.4 billion, up 3.7% compared to prior year GAAP diluted EPS of $0.88 a
CVS Health Corporation reported its first quarter 2024 results, with total revenues reaching $88.4 billion, marking a 3.7% increase from the previous year. However, the company revised its full-year 2024 financial guidance, lowering expectations for both GAAP diluted EPS and adjusted EPS due to challenges in its Medicare Advantage segment. The CEO emphasized confidence in the company's long-term strategy despite the current challenges affecting profitability. The performance of the Health Services segment was notably impacted by the loss of a large client and continued pharmacy client price improvements.
Read more →-CVS
Feb 7, 2024CVS HEALTH REPORTS FOURTH QUARTER AND FULL-YEAR 2023 RESULTS WOONSOCKET
CVS Health Corporation has reported its financial results for the fourth quarter and full year of 2023, showcasing increased total revenues of 11.9% in Q4 and 10.9% for the year. Despite this growth, the company experienced a decline in operating income and adjusted EPS for Q4. CVS introduced new pricing models aimed at enhancing transparency in drug reimbursements and announced a dividend increase, reflecting confidence in future performance. Guidance for 2024 shows revised earnings expectations due to anticipated medical cost trends.
Read more →-CVS
Jan 5, 2024CVS Health Announces Leadership Appointments Thomas F. Cowhey Named Chief Financial Officer Mike Pykosz Named President of Health Care Delivery WOONSOCKET, R.I.
CVS Health has announced several leadership appointments, naming Thomas F. Cowhey as the new Chief Financial Officer and Mike Pykosz as President of Health Care Delivery. Cowhey, who has been with CVS since 2022, brings significant healthcare financial management experience. Pykosz, co-founder of Oak Street Health, will work to unify CVS's care delivery assets and enhance its healthcare strategy. The changes come as CVS continues to prioritize patient care through innovative solutions and leadership continuity.
Read more →-CVS
Dec 5, 2023CVS Health highlights path to accelerating long-term growth through building a world of health around every consumer Introduces CVS CostVantage TM and CVS Caremark TrueCost TM to drive aligned incentives and deliver a mo
CVS Health has outlined its strategy to drive long-term growth through innovative models and increased integration of services. At the 2023 Investor Day, CVS introduced CVS CostVantage and CVS Caremark TrueCost to enhance transparency in pharmacy reimbursement. Additionally, CVS launched its Health Services brand, CVS Healthspire, aimed at improving consumer access to care. The company also announced a 10% increase in its quarterly dividend and reiterated its 2023 financial guidance while providing optimistic projections for 2024.
Read more →-CVS
Nov 1, 2023CVS Health reports third quarter results WOONSOCKET
CVS Health Corporation reported its third quarter financial results for 2023, posting total revenues of $89.8 billion, reflecting a 10.6% increase compared to the previous year. The company achieved operating income of $3.7 billion, a significant rebound from a loss the previous year, primarily due to the absence of large legal charges. Significant developments included the successful launch of Cordavis™, a subsidiary aimed at biosimilars, and enhancements to Aetna's Medicare offerings. Despite positive operational results, the firm noted challenges such as increased interest expenses and a slight decline in Medicaid membership.
Read more →-CVS
Oct 16, 2023CVS Health announces CFO Shawn Guertin to take leave of absence due to family health reasons SVP of Corporate Finance Thomas F. Cowhey Appointed Interim CFO CEO of Oak Street Health Mike Pykosz Named Interim President of
CVS Health announced that CFO Shawn Guertin will take a leave of absence due to family health reasons. Thomas F. Cowhey, SVP of Corporate Finance, has been appointed as the Interim CFO while Mike Pykosz, CEO of Oak Street Health, will serve as Interim President of Health Services. The leadership changes are aimed at maintaining operational continuity during Guertin's absence. CVS Health is still on track to report its third quarter earnings on November 1, 2023, and will hold its Investor Day on December 5, 2023.
Read more →-CVS
Oct 13, 2023Eighty-seven (87) percent of Aetna Medicare Advantage members in 4-star plans or higher for 2024 Commitment to exceptional service for members across the nation drove a significant improvement in member experience rating
CVS Health's Aetna announced that 87% of its Medicare Advantage members are enrolled in plans rated 4 stars or higher for 2024 by the Centers for Medicare Medicaid Services (CMS). This achievement reflects substantial improvements in member experience ratings and health outcomes, especially in critical areas such as care coordination and disease management. Aetna's leadership is committed to maintaining high standards of service and continuous enhancement of member experiences.
Read more →-CVS
Aug 23, 2023CVS Health Launches Cordavis New business will bring high quality biosimilar products to market with goal of reducing drug spend and ensuring access to affordable medications Cordavis to launch biosimilar H
CVS Health has launched a new subsidiary called Cordavis to bring high-quality biosimilar products to the U.S. market. The first product, Hyrimoz, is a biosimilar for Humira and will be available in 2024 at more than 80% lower list price than its reference product. This initiative aims to reduce drug costs and increase access to affordable medications, with the U.S. biosimilars market projected to grow significantly over the coming years. CVS Health emphasizes their commitment to ensuring a consistent supply of these products, which can potentially improve health outcomes for consumers.
Read more →-CVS
Aug 2, 2023CVS Health reports second quarter results WOONSOCKET
CVS Health Corporation reported its second quarter results for 2023, highlighting a total revenue increase to $88.9 billion, up 10.3% year-over-year. However, the operating income saw a significant decline of 30.7%, primarily due to restructuring charges and integration costs from recent acquisitions. The company revised its full-year GAAP diluted EPS guidance down to a range of $6.53 to $6.75 while confirming the adjusted EPS guidance. Additionally, CVS launched a new program, Caremark Cost SaverTM, to help lower pharmacy costs for its clients.
Read more →-CVS
May 3, 2023CVS HEALTH REPORTS FIRST QUARTER RESULTS, COMPLETES ACQUISITIONS OF SIGNIFY HEALTH AND OAK STREET HEALTH WOONSOCKET
CVS Health Corporation reported its first-quarter results for 2023, showing a revenue increase of 11% year-over-year to $85.3 billion, but operating income fell by 2.8%. The company completed acquisitions of Signify Health and Oak Street Health, which are expected to bolster its value-based care services. Despite positive revenue growth, CVS revised its full-year EPS guidance downward and reported a decline in adjusted operating income. Overall, the performance reflects both growth potential and ongoing challenges in specific segments.
Read more →-CVS
May 2, 2023CVS Health completes acquisition of Oak Street Health WOONSOCKET, R.I.
CVS Health has successfully completed its acquisition of Oak Street Health, which is expected to enhance its value-based primary care services. The acquisition, finalized at $39 per share, amounts to an enterprise value of approximately $10.6 billion. This strategic move is projected to improve health outcomes while reducing costs for patients, particularly in underserved areas. CVS will discuss this acquisition further during its upcoming earnings conference call.
Read more →-CVS
Feb 8, 2023Form of Voting and Support Agreement This VOTING AND SUPPORT AGREEMENT, dated as of February [ ], 2023 (this " Agreement "), by and among Oak Street Health, Inc., a Delaware corporation (the " Company "), the stockholder
The Voting and Support Agreement between Oak Street Health, Inc. and CVS Pharmacy, Inc. outlines the terms under which stockholders agree to support a merger between the two entities. This agreement includes conditions for voting on the merger at stockholder meetings and restrictions on transferring shares during the agreement period. CVS, through its wholly owned subsidiary Merger Sub, will merge with Oak Street Health to create a wholly owned subsidiary under CVS. The document establishes guidelines to ensure stockholders do not enter into conflicting agreements that might hinder the merger process.
Read more →-CVS
Feb 8, 2023CVS HEALTH REPORTS STRONG FOURTH QUARTER AND FULL-YEAR 2022 RESULTS WOONSOCKET
CVS Health Corporation reported strong financial results for the fourth quarter and full year ending December 31, 2022, with a revenue increase of 9.5% and 10.4% respectively. The company generated $16.2 billion in cash flow from operations and raised its quarterly dividend by 10%. However, operating income for the year decreased by 41.3% due to opioid litigation charges and a significant loss from its Omnicare business. CVS also finalized its acquisition of Signify Health, expanding its capabilities in home health care.
Read more →-CVS
Feb 8, 2023CVS Health to Acquire Oak Street Health Acquisition further advances CVS Health's care delivery strategy for consumers WOONSOCKET, R.I., CHICAGO
CVS Health has agreed to acquire Oak Street Health for approximately $10.6 billion, with the aim of enhancing care delivery, particularly for underserved populations. This acquisition will allow CVS Health to better integrate technology and expand its primary care offerings. Oak Street Health's leadership will remain intact post-acquisition, focusing on improving health outcomes and efficiencies within their care model. The transaction is expected to close in 2023, pending regulatory and shareholder approvals.
Read more →-CVS
Jan 23, 2023CVS Health Names David Joyner Head of Pharmacy Services; Amy Bricker Becomes Chief Product Officer - Consumer WOONSOCKET, R.I.
CVS Health has announced the appointment of David Joyner as the Executive Vice President and President of Pharmacy Services, and Amy Bricker as the Executive Vice President and Chief Product Officer - Consumer. Joyner brings over 34 years of experience and will lead CVS Caremark, while Bricker, with nearly 20 years in health care, will focus on consumer products and innovation. These hires indicate CVS Health's continued strategic emphasis on enhancing consumer health care experiences.
Read more →-CVS
Nov 2, 2022CVS HEALTH REPORTS THIRD QUARTER RESULTS WOONSOCKET
CVS HEALTH REPORTS THIRD QUARTER RESULTS WOONSOCKET, RHODE ISLAND, November 2, 2022 - CVS Health Corporation (NYSE CVS) today announced operating results for the three months ended September 30, 2022. Total revenues increased to $81.2 billion, up 10.0% compared to prior year GA
Read more →-CVS
Sep 5, 2022CVS Health to Acquire Signify Health Advances long-term strategy by providing platform for growth in value-based care WOONSOCKET, R.I., DALLAS and
CVS Health to Acquire Signify Health Advances long-term strategy by providing platform for growth in value-based care WOONSOCKET, R.I., DALLAS and NEW YORK, Sept. 5, 2022 CVS Health (NYSE: CVS ) and Signify Health (NYSE: SGFY ) ( Signify ) have entered into a definitive agreeme
Read more →-CVS
Sep 2, 2022VOTING AGREEMENT VOTING AGREEMENT, dated as of
VOTING AGREEMENT VOTING AGREEMENT, dated as of September 2, 2022 (this Voting Agreement ), among CVS Pharmacy, Inc., a Rhode Island corporation ( Parent ), and the stockholders of Signify Health, Inc., a Delaware corporation (the Company ), listed on the signature pages hereto (
Read more →-CVS
Aug 3, 2022CVS HEALTH REPORTS STRONG SECOND QUARTER RESULTS, RAISES 2022 FULL-YEAR EPS AND CASH FLOW FROM OPERATIONS GUIDANCE WOONSOCKET
CVS HEALTH REPORTS STRONG SECOND QUARTER RESULTS, RAISES 2022 FULL-YEAR EPS AND CASH FLOW FROM OPERATIONS GUIDANCE WOONSOCKET, RHODE ISLAND, August 3, 2022 - CVS Health Corporation (NYSE CVS) today announced operating results for the three months ended June 30, 2022. Total reven
Read more →-CVS
May 4, 2022CVS HEALTH REPORTS STRONG FIRST QUARTER RESULTS WOONSOCKET
CVS HEALTH REPORTS STRONG FIRST QUARTER RESULTS WOONSOCKET, RHODE ISLAND, May 4, 2022 - CVS Health Corporation (NYSE CVS) today announced operating results for the three months ended March 31, 2022. Total revenues increased to $76.8 billion, up 11.2% compared to prior year GAAP
Read more →-CVS
Mar 30, 2022CVS Health Reaches Opioid Settlement Agreement with State of Florida WOONSOCKET, R.I.
CVS Health Reaches Opioid Settlement Agreement with State of Florida WOONSOCKET, R.I., March 30, 2022 - CVS Health (NYSE: CVS) announced today that it has entered into an agreement with the State of Florida to resolve claims dating back more than a decade related to prescription
Read more →-CVS
Mar 10, 2022CHARTER 2 ss850270_ex9901.htm PRESS RELEASE CVS Health Announces Changes to Board of Directors Independent Chair David W. Dorman and Director Tony L. White to Retire Board of Directors Selects Roger N. Farah as Next Inde
CVS Health Announces Changes to Board of Directors Independent Chair David W. Dorman and Director Tony L. White to Retire Board of Directors Selects Roger N. Farah as Next Independent Chair WOONSOCKET, R.I, March 10, 2022 - CVS Health Corporation (NYSE: CVS) today announced th
Read more →-CVS
Feb 9, 2022CVS HEALTH REPORTS STRONG FOURTH QUARTER AND FULL-YEAR 2021 RESULTS, CONFIRMS 2022 FULL-YEAR EPS GUIDANCE WOONSOCKET
CVS HEALTH REPORTS STRONG FOURTH QUARTER AND FULL-YEAR 2021 RESULTS, CONFIRMS 2022 FULL-YEAR EPS GUIDANCE WOONSOCKET, RHODE ISLAND, February 9, 2022 - CVS Health Corporation (NYSE CVS) today announced operating results for the three months and year ended December 31, 2021. Total
Read more →-CVS
Dec 9, 2021CVS Health Presents Strategy for Revolutionizing Consumer Health Experience While Driving Profitable Growth Advancement of Health Services and Primary Care Capabilities Will Augment Performance in Foundational Businesses
CVS Health Presents Strategy for Revolutionizing Consumer Health Experience While Driving Profitable Growth Advancement of Health Services and Primary Care Capabilities Will Augment Performance in Foundational Businesses While Creating New Opportunities in High-Growth Markets U
Read more →-CVS
Nov 18, 2021CVS Health Announces Steps to Accelerate Omnichannel Health Strategy Prem Shah to become company's first Chief Pharmacy Officer Shah and Michelle Peluso named Co-Presidents of retail business effective
CVS Health Announces Steps to Accelerate Omnichannel Health Strategy Prem Shah to become company's first Chief Pharmacy Officer Shah and Michelle Peluso named Co-Presidents of retail business effective January 1, 2022 New retail footprint strategy aligned to evolving consumer
Read more →-CVS
Nov 3, 2021CVS HEALTH REPORTS STRONG THIRD QUARTER RESULTS KEY FINANCIAL DATA THIRD QUARTER HIGHLIGHTS WOONSOCKET
WOONSOCKET, RHODE ISLAND, November 3, 2021 - CVS Health Corporation (NYSE CVS) today announced operating results for the three months ended September 30, 2021. Three Months Ended September 30, In millions, except per share amounts 2021 2020 Change Total revenues $ 73,794 $
Read more →-CVS
Aug 23, 2021Investor Susie Lisa, CFA Media T.J. Crawford Contact: Senior Vice President Contact: Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 FOR IMMEDIATE RELEASE CVS Health Corporation Announces
FOR IMMEDIATE RELEASE CVS Health Corporation Announces Early Results and Upsize of Previously Announced Cash Tender Offer to an Aggregate Principal Amount of $2,049,919,000 from $2,000,000,000 WOONSOCKET, RI, August 23, 2021 CVS Health Corporation ( CVS Health , NYSE: CVS) ann
Read more →-CVS
Aug 9, 2021Investor Susie Lisa Media T.J. Crawford Contact: Senior Vice President Contact: Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 FOR IMMEDIATE RELEASE CVS Health Corporation Announces Cash
FOR IMMEDIATE RELEASE CVS Health Corporation Announces Cash Tender Offer for its 4.300% Senior Notes due 2028 WOONSOCKET, RI, August 9, 2021 CVS Health Corporation ( CVS Health , NYSE: CVS) announced today that it has commenced a cash tender offer (the Tender Offer ) for up t
Read more →-CVS
Aug 4, 2021Investor Susie Lisa, CFA Media T.J. Crawford Contact Senior Vice President Contact Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 FOR IMMEDIATE RELEASE CVS HEALTH REPORTS STRONG SECOND Q
Investor Susie Lisa, CFA Media T.J. Crawford Contact Senior Vice President Contact Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 CVS HEALTH REPORTS STRONG SECOND QUARTER RESULTS RAISES 2021 FULL YEAR EPS AND CASH FLOW FROM OPERATIONS GUIDA
Read more →-CVS
May 18, 2021CVS Health Appoints Shawn Guertin Chief Financial Officer Woonsocket, R.I.
CVS Health Appoints Shawn Guertin Chief Financial Officer Woonsocket, R.I., May 18, 2021 - CVS Health (NYSE: CVS) today announced it has appointed Shawn Guertin as Executive Vice President and Chief Financial Officer, effective May 28, 2021. "Shawn is an extraordinary leader wi
Read more →-CVS
May 4, 2021Investor Katie Durant Media T.J. Crawford Contact Senior Director Contact Vice President Investor Relations External Affairs (401) 770-6442 (212) 457-0583 FOR IMMEDIATE RELEASE CVS HEALTH REPORTS STRONG FIRST QUARTER RES
Investor Katie Durant Media T.J. Crawford Contact Senior Director Contact Vice President Investor Relations External Affairs (401) 770-6442 (212) 457-0583 CVS HEALTH REPORTS STRONG FIRST QUARTER RESULTS RAISES 2021 FULL YEAR EPS AND CONFIRMS CASH FLOW FROM OPERATIONS GUIDAN
Read more →-CVS
Feb 16, 2021Investor Valerie Haertel Media T.J. Crawford Contact Senior Vice President Contact Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 FOR IMMEDIATE RELEASE CVS HEALTH REPORTS FOURTH QUARTER
Investor Valerie Haertel Media T.J. Crawford Contact Senior Vice President Contact Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 CVS HEALTH REPORTS FOURTH QUARTER AND FULL-YEAR 2020 RESULTS AND PROVIDES 2021 FULL YEAR GUIDANCE Full Year a
Read more →-CVS
Dec 21, 2020Investor Valerie Haertel Media T.J. Crawford Contact: Senior Vice President Contact: Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 FOR IMMEDIATE RELEASE CVS Health Corporation Announces
FOR IMMEDIATE RELEASE CVS Health Corporation Announces Early Results and Upsize of Previously Announced Cash Tender Offers to an Aggregate Principal Amount of $4,500,000,000 from $4,000,000,000 of Certain Outstanding Notes WOONSOCKET, RI, December 21, 2020 CVS Health Corporati
Read more →-CVS
Nov 6, 2020CVS Health Announces CEO Transition Effective February 2021 Karen S. Lynch Named the Next President and CEO of CVS Health and Larry J. Merlo to Retire in Spring 2021 WOONSOCKET, R.I.
CVS Health Announces CEO Transition Effective February 2021 Karen S. Lynch Named the Next President and CEO of CVS Health and Larry J. Merlo to Retire in Spring 2021 WOONSOCKET, R.I., Nov. 6, 2020 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) today announced that its Board
Read more →-CVS
Nov 6, 2020Investor Valerie Haertel Media T.J. Crawford Contact Senior Vice President Contact Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 FOR IMMEDIATE RELEASE CVS HEALTH REPORTS THIRD QUARTER R
Investor Valerie Haertel Media T.J. Crawford Contact Senior Vice President Contact Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 CVS HEALTH REPORTS THIRD QUARTER RESULTS WITH DIVERSIFIED ASSETS DELIVERING STRONG ENTERPRISE PERFORMANCE 202
Read more →-CVS
Sep 25, 2020STOCKHOLDER PRESENTATION Fall 2020 Stockholder Engagement 2 Cautionary statement concerning forward - looking statements Non - GAAP financial measures This presentation includes forward - looking statements. The Private
Fall 2020 Stockholder Engagement 2 Cautionary statement concerning forward - looking statements Non - GAAP financial measures This presentation includes forward - looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harb or for forward - looki
Read more →-CVS
Aug 5, 2020Investor Valerie Haertel Media T.J. Crawford Contact: Senior Vice President Contact: Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 FOR IMMEDIATE RELEASE CVS HEALTH REPORTS SECOND QUARTE
Investor Valerie Haertel Media T.J. Crawford Contact: Senior Vice President Contact: Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 CVS HEALTH REPORTS SECOND QUARTER RESULTS; DIVERSIFIED ASSETS DELIVER STRONG ENTERPRISE RESULTS 2020 FULL YE
Read more →-CVS
May 6, 2020Investor Valerie Haertel Media T.J. Crawford Contact: Senior Vice President Contact: Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 FOR IMMEDIATE RELEASE CVS HEALTH REPORTS FIRST QUARTER
Investor Valerie Haertel Media T.J. Crawford Contact: Senior Vice President Contact: Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 CVS HEALTH REPORTS FIRST QUARTER RESULTS, PROVIDES UPDATE ON COVID-19 RESPONSE 2020 FULL YEAR EPS GUIDANCE R
Read more →-CVS
Feb 12, 2020to the Company's Current Report on Form 8-K filed with the SEC on
Investor Valerie Haertel Media T.J. Crawford Contact: Senior Vice President Contact: Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 CVS HEALTH REPORTS FOURTH QUARTER AND FULL-YEAR 2019 RESULTS, REFLECTING STRONG EXECUTION ACROSS THE ENTERPR
Read more →-CVS
Feb 3, 2020Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. By their nature, all forward-looking s
CVS Health Announces Upcoming Changes to Board of Directors Board Will Transition from 16 to 13 Directors WOONSOCKET, R.I., Feb. 3, 2020 - CVS Health (NYSE: CVS) today announced upcoming changes to its Board of Directors (the "Board"). Richard "Dick" Swift, Richard Bracken and
Read more →-CVS
Nov 6, 2019Investor Valerie Haertel Media T.J. Crawford Contact: Senior Vice President Contact: Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 FOR IMMEDIATE RELEASE CVS HEALTH REPORTS THIRD QUARTER
Investor Valerie Haertel Media T.J. Crawford Contact: Senior Vice President Contact: Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 CVS HEALTH REPORTS THIRD QUARTER RESULTS 2019 EPS GUIDANCE RAISED AND NARROWED, REFLECTING STRONG EXECUTION
Read more →-CVS
Aug 8, 2019of CVS Health's Current Report on Form 8-K or any of the Company's other SEC filings. In accordance with guidance provided by the SEC regarding use by a company of its websites and social media channels as a means to dis
Item 1. Business with Retrospective Application of Segments CVS Health Corporation, together with its subsidiaries (collectively, "CVS Health," the "Company," "we," "our" or "us"), is the nation's premier health innovation company helping people on their path to better health. W
Read more →-CVS
Jun 4, 2019CVS HEALTH OUTLINES STRATEGY TO ACCELERATE GROWTH Significant Expansion of HealthHUBs will Help Drive Differentiated, Consumer-Centric Health Experience; 1,500 Expected to Open by End of 2021 Strong Execution on Aetna In
CVS HEALTH OUTLINES STRATEGY TO ACCELERATE GROWTH Significant Expansion of HealthHUBs will Help Drive Differentiated, Consumer-Centric Health Experience; 1,500 Expected to Open by End of 2021 Strong Execution on Aetna Integration Projected to Drive Approximately $300 - $350 Mil
Read more →-CVS
May 1, 2019Investor Joe Krocheski Media T.J. Crawford Contact: Vice President Contact: Vice President Investor Relations External Affairs (860) 273-0896 (212) 457-0583 FOR IMMEDIATE RELEASE CVS HEALTH REPORTS FIRST QUARTER RESULTS
Investor Joe Krocheski Media T.J. Crawford Contact: Vice President Contact: Vice President Investor Relations External Affairs (860) 273-0896 (212) 457-0583 CVS HEALTH REPORTS FIRST QUARTER RESULTS 2019 EPS GUIDANCE RAISED AND NARROWED TO REFLECT STRONG PERFORMANCE YEAR-TO
Read more →-CVS
Feb 20, 2019Investor Mike McGuire Media T.J. Crawford Contact: Senior Vice President Contact: Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 FOR IMMEDIATE RELEASE CVS HEALTH REPORTS FOURTH QUARTER A
Investor Mike McGuire Media T.J. Crawford Contact: Senior Vice President Contact: Vice President Investor Relations External Affairs (401) 770-4050 (212) 457-0583 CVS HEALTH REPORTS FOURTH QUARTER AND FULL YEAR RESULTS AND PROVIDES 2019 FULL YEAR GUIDANCE Fourth Quarter Ye
Read more →-CVS
Nov 28, 2018CVS Health Completes Acquisition of Aetna, Marking the Start of Transforming the Consumer Health Experience Combined company brings together capabilities of two leading organizations to establish innovative health care m
CVS Health Completes Acquisition of Aetna, Marking the Start of Transforming the Consumer Health Experience Combined company brings together capabilities of two leading organizations to establish innovative health care model Care delivery will have a local focus that will mak
Read more →-CVS
Nov 6, 2018Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President Investor Relations Corporate Communications (401) 770-4050 (401) 770-5717 FOR IMMEDIATE RELEASE CVS HEALTH REPORTS THIRD Q
FOR IMMEDIATE RELEASE CVS HEALTH REPORTS THIRD QUARTER RESULTS Third Quarter Year-over-Year Highlights: Year-to-date Highlights: 2018 Confirmed Full Year Guidance: WOONSOCKET, RHODE ISLAND, November 6, 2018 - CVS Health Corporation (NYSE: CVS) today announced operating resul
Read more →-CVS
Oct 22, 2018CVS Health Names James Clark Senior Vice President and Chief Accounting Officer Upon Closing of Aetna Acquisition Woonsocket, RI (
CVS Health Names James Clark Senior Vice President and Chief Accounting Officer Upon Closing of Aetna Acquisition Woonsocket, RI (October 22, 2018) CVS Health (NYSE: CVS) today announced that James D. Clark, currently Vice President Finance and Accounting for CVS Health, will a
Read more →-CVS
Oct 10, 2018CVS Health Provides Update to Board and Management Roles Upon Closing of Aetna Acquisition Will expand Board to include three additional Aetna Directors with deep insurance company oversight experience Eva Boratto to bec
CVS Health Provides Update to Board and Management Roles Upon Closing of Aetna Acquisition Will expand Board to include three additional Aetna Directors with deep insurance company oversight experience Eva Boratto to become CFO; Shawn Guertin to remain with company for transit
Read more →-CVS
Oct 10, 2018CVS Health Acquisition of Aetna Moving Forward on Agreement with U.S. Department of Justice Transaction on track to close in early part of Q4 2018 Woonsocket, RI (
CVS Health Acquisition of Aetna Moving Forward on Agreement with U.S. Department of Justice Transaction on track to close in early part of Q4 2018 Woonsocket, RI (October 10, 2018) CVS Health (NYSE: CVS) today announced that it has entered into an agreement with the U.S. Depar
Read more →-CVS
Aug 8, 2018Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President Investor Relations Corporate Communications (401) 770-4050 (401) 770-5717 FOR IMMEDIATE RELEASE CVS HEALTH REPORTS SECOND
FOR IMMEDIATE RELEASE CVS HEALTH REPORTS SECOND QUARTER RESULTS Second Quarter Year-over-Year Highlights: Year-to-date Highlights: 2018 Full Year Guidance: WOONSOCKET, RHODE ISLAND, August 8, 2018 - CVS Health Corporation (NYSE: CVS) today announced operating results for the
Read more →-CVS
Jul 25, 2018forms a part, or to reflect the occurrence of unanticipated events, even in the event that any or all of the assumptions are shown to be in error. The following table presents the prospective financial information that w
Cautionary Statement Regarding Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 (the Reform Act ) provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation ( CVS Health ) or Aetna, Inc. ( Aetna ). This Exh
Read more →-CVS
Jun 6, 2018CVS Health Announces Management Team for Combined Company Following Close of Aetna Acquisition Transaction Executives of both companies appointed to drive forward future vision Transaction expected to close in second hal
CVS Health Announces Management Team for Combined Company Following Close of Aetna Acquisition Transaction Executives of both companies appointed to drive forward future vision Transaction expected to close in second half of 2018, subject to required regulatory approvals Woon
Read more →-CVS
May 2, 2018Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President Investor Relations Corporate Communications (401) 770-4050 (401) 770-5717 FOR IMMEDIATE RELEASE CVS HEALTH REPORTS FIRST Q
FOR IMMEDIATE RELEASE CVS HEALTH REPORTS FIRST QUARTER RESULTS AND CONFIRMS 2018 FULL YEAR OUTLOOK First Quarter Year-over-Year Highlights: 2018 Full Year Guidance: WOONSOCKET, RHODE ISLAND, May 2, 2018 - CVS Health Corporation (NYSE: CVS) today announced operating results f
Read more →-CVS
Mar 13, 2018CVS Health Stockholders Approve Aetna Acquisition Transaction expected to close in second half of 2018, subject to regulatory approvals Combined company will focus on remaking the consumer health care experience, lowerin
CVS Health Stockholders Approve Aetna Acquisition Transaction expected to close in second half of 2018, subject to regulatory approvals Combined company will focus on remaking the consumer health care experience, lowering health care costs WOONSOCKET, R.I., March 13, 2018 In
Read more →-CVS
Mar 6, 2018to this Current Report on Form 8-K for a discussion of the risks related to operating globally. Anti-Money Laundering Regulations Certain of our lines of business are subject to Treasury anti-money laundering regulations
The following sets forth the Business discussion and Regulatory Environment discussion of Aetna Inc. ( Aetna ) and its subsidiaries described in Part I, Item 1 and Part II, Item 7 in Aetna s Annual Report on Form 10-K for the year ended December 31, 2017 and filed with the Securi
Read more →-CVS
Feb 28, 2018to this Current Report on Form 8-K for a description of share repurchases. 80
Consolidated Balance Sheets Refer to accompanying Notes to Consolidated Financial Statements. Consolidated Statements of Income Refer to accompanying Notes to Consolidated Financial Statements. Consolidated Statements of Comprehensive Income Refer to accompanying Notes to Co
Read more →-CVS
Feb 8, 2018Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President Investor Relations Corporate Communications (401) 770-4050 (401) 770-5717 FOR IMMEDIATE RELEASE CVS HEALTH REPORTS FOURTH
FOR IMMEDIATE RELEASE CVS HEALTH REPORTS FOURTH QUARTER RESULTS AND UPDATES 2018 FULL-YEAR OUTLOOK FOR INVESTMENTS FROM TAX REFORM Fourth Quarter Year-over-year Highlights: Full Year Highlights: WOONSOCKET, RHODE ISLAND, February 8, 2018 - CVS Health Corporation (NYSE: CVS)
Read more →-CVS
Jan 4, 2018CVS Health Provides 2018 Outlook Expect Adjusted Consolidated Operating Profit Growth of 1% to 4% Enterprise Script Growth and Benefits from Streamlining Initiative Driving Solid Growth Fourth Quarter and Full-year 2017
CVS Health Provides 2018 Outlook Expect Adjusted Consolidated Operating Profit Growth of 1% to 4% Enterprise Script Growth and Benefits from Streamlining Initiative Driving Solid Growth Fourth Quarter and Full-year 2017 Consolidated Expectations Confirmed Fourth Quarter and F
Read more →Competitive Position
How CVS ranks across every disease it competes inCompetitive Position is a premium feature
See how CVS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial